Detalhe da pesquisa
1.
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Br J Haematol
; 184(2): 215-222, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30183069
2.
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Blood
; 127(1): 79-86, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472752
3.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27982425
4.
Molecular monitoring of response in patients with chronic myeloid leukemia.
Manag Care
; 22(7): 40, 50-61, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23936973
5.
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631112
6.
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 27(5): 476-81, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18953490
7.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 35(31): 3538-3546, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862883
8.
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.
Ther Adv Hematol
; 4(3): 157-71, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23730494
9.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
J Clin Oncol
; 31(1): 88-94, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23045577